⌕
Alto Neuroscience · ANRO · NYSE
Tenet 52 · Mixed
Compare
$27.12−8.19%At closeTenet 52 · Mixed
$27.12−2.42 (−8.19%)
At close: Nov 16, 2026, 4:00 PM ET· NYSE · USD

Alto Neuroscience (ANRO) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld.
The four lines that matter · FY23–FY25
Revenue ($M)—
0.0
FY23→FY25CAGR —
Net income ($M)▼2.9%
−63.2
FY23→FY25CAGR —
Free cash flow ($M)▼4.6%
−51.8
FY23→FY25CAGR —
Diluted EPS▲12.4%
−2.19
FY23→FY25CAGR —
What the income statement says · FY23–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit−45.6R&D−20.7SG&A−66.4Op income3.1Tax & other−63.2Net income

Margin trend · direction beats level
108530%sector median net margin ~4%FY23FY25

This filer reports no gross profit or operating income line, so those margins are not drawn.

The receipt · income statement · FY23–FY25 USD millions except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.6201, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23YoYCAGR 23→25
Revenue & profitability
Revenue
—0.00.00.0——
Cost of revenue
—0.00.00.0——
Gross profit
—0.00.00.0——
Research & development
72.645.647.030.3▼2.9%+22.7%
Selling, general & admin
28.020.721.67.5▼4.0%+66.1%
Total operating expenses
100.566.468.637.8▼3.3%+32.5%
Operating incomefeeds ROC rank
−100.5−66.4−68.6−37.8▲3.3%—
Other income, net
5.43.17.21.5——
Pretax income
−95.2−63.2−61.4−36.3▼2.9%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−95.2−63.2−61.4−36.3▼2.9%—
Per share
Diluted EPSbuyback-sensitive
−2.45−2.19−2.50−9.73▲12.4%—
Diluted shares (mn)
46.5328.8524.603.73▲17.3%+178.1%
Margins
† TTM = trailing four quarters through 2026-09-30.
CSV export is on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-16 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.